New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. - Test2 - elhamkhani - TriplyDB

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.

http://www.wikidata.org/entity/Q34375466

about

A clinical approach to obstructive sleep apnea as a risk factor for cardiovascular disease Understanding heart failure with preserved ejection fraction: where are we today?Left ventricular function assessment in cirrhosis: Current methods and future directions.Addressing the Heterogeneity of Heart Failure in Future Randomized Trials.Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.Ergospirometry and echocardiography in early stage of heart failure with preserved ejection fraction and in healthy individuals.Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction.EPA, not DHA, prevents fibrosis in pressure overload-induced heart failure: potential role of free fatty acid receptor 4 Biomechanics of Cardiac Function Altered Metabolic Profile With Sodium-Restricted Dietary Approaches to Stop Hypertension Diet in Hypertensive Heart Failure With Preserved Ejection Fraction.Left atrial minimum volume is more strongly associated with N-terminal pro-B-type natriuretic peptide than the left atrial maximum volume in a community-based sample Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Functional characterization of human umbilical cord-derived mesenchymal stem cells for treatment of systolic heart failure Coronary microcirculatory pathophysiology: can we afford it to remain a black box?The EHJ: the first years and the future.Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations.The (dys)functional extracellular matrix.Heart failure with preserved ejection fraction: uncertainties and dilemmas.Cardiac Physiology of Aging: Extracellular Considerations.Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use.Sleep disordered breathing in older adults with heart failure with preserved ejection fraction.Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.Win Ratio -An Intuitive and Easy-To-Interpret Composite Outcome in Medical Studies Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review.Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.Towards Precision in HF Pharmacotherapy.Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine.Phenotype-Specific Association of Single-Nucleotide Polymorphisms with Heart Failure and Preserved Ejection Fraction: a Genome-Wide Association Analysis of the Cardiovascular Health Study.ω3-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4.Atrial-focused views improve the accuracy of two-dimensional echocardiographic measurements of the left and right atrial volumes: a contribution to the increase in normal values in the guidelines update.Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.Amyloid Light-Chain Amyloidosis Manifesting as Heart Failure with Preserved Ejection Fraction in a Patient with Hyper-Immunoglobulin E-emia.Five-year changes in cardiac structure and function in patients with rheumatoid arthritis compared with the general population.Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.Association of worsening arterial stiffness with incident heart failure in asymptomatic patients with cardiovascular risk factors.Heterogeneous responses of systolic and diastolic left ventricular function to exercise in patients with heart failure and preserved ejection fraction The Potential of Clinical Phenotyping of Heart Failure With Imaging Biomarkers for Guiding Therapies: A Focused Update.

P2860

Q26751303-A33A2CC7-7618-46B0-ADF6-EB8F76AC4A52 Q26766590-8A5BB486-189D-49C1-BA03-628A639F368F Q26769598-FC5C6928-C982-4A80-9D99-3F8AFA8C3CFB Q30234708-9BA5512E-A1B7-4A86-BB87-CEF61407129D Q33791471-CFDB7409-5414-454D-927F-A4764303F03F Q34487487-DDBA77FB-F32B-45FD-93D3-465707DB25FA Q36117014-7B11A2D5-7097-411D-A89E-ED9D58A24DE5 Q36266675-A020F528-5E83-4D6C-A9AA-8D95BD1E6D1E Q36307290-D81DE9C8-82C7-4280-A395-05DCE4CBDB2F Q36343041-3AE0E129-FD0D-4641-AC64-F8CFA05776AB Q36483094-6DFBB66B-3FED-4F82-AE81-B0D2214F4A0E Q36573363-01C90533-F22C-4310-89C7-B71F91FB2D52 Q36715249-46322B34-B719-4EC8-834C-06373F7B5823 Q37058596-61F0B810-7282-4D65-912D-3F17A6AEB3D1 Q37406578-BAF6CF6A-74C4-485D-81EB-5146E971AD6F Q37738588-F40E32E4-0BD2-48BA-83D1-B1FB055D532B Q38270448-9925F928-BBCD-4F66-9415-4A0FC53CD839 Q38430272-A16AEC30-2F37-48A8-953D-0FBC59E73987 Q38452473-D200FAC4-A68B-45C8-803A-A5994A76D260 Q38529003-5E7DD0CF-83E9-444D-A179-59BEA8D5902D Q38542448-4B13537C-E822-42D6-BB58-805A3F54C737 Q38614176-E83ED775-B7B3-4C38-9169-022B951548F9 Q38636431-DA02D367-6C31-4DA1-9168-A5AC2CD63587 Q38638655-983CACFC-52FA-4670-A426-D84B386C2D3B Q38645812-FBC366CE-9C14-4135-9C8E-190CA0DE5938 Q38646405-AF0650C7-49EC-4C34-B90E-385B85DDF68A Q38658569-16E64677-DAF7-4BE6-8EB7-24E72C5A19D4 Q38691846-9C7AA746-05C7-49E4-BF14-2806A5EEDA5D Q38758440-F911D020-B5B4-46B4-B138-35E7F992B4E4 Q38764956-C25808C3-97C6-4C07-B746-CFCC0292019A Q39010896-B6CA3834-1E4B-4CEA-A6EB-0BDD817A9FF1 Q39041784-2213C114-C9A8-4199-8AFF-D20D200B8914 Q39329036-B1FD9398-061C-460C-B166-299A6F1BDCC4 Q40000430-1D9AFA20-1437-4CD5-8879-23ACC0763001 Q40084324-C6807CAE-707F-4943-BF08-1BDE29F131D4 Q40233931-5D6C8CA4-10CF-41C2-8B2A-C73168A9C2F4 Q40401140-932F979B-1FB4-4FF5-A49E-01F287F9B2C6 Q40599528-457CD458-7412-4537-AA65-CAAAA31A31E0 Q41225769-926AB6BA-4994-4130-B5DB-49078120A923 Q41693071-1EEF44A4-9EDA-49BB-995E-2E848559289F

P2860

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.

http://www.wikidata.org/entity/Q34375466

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

New strategies for heart failu ...... for heart failure phenotypes.

@ast

New strategies for heart failu ...... for heart failure phenotypes.

@en

New strategies for heart failu ...... for heart failure phenotypes.

@nl

type

label

New strategies for heart failu ...... for heart failure phenotypes.

@ast

New strategies for heart failu ...... for heart failure phenotypes.

@en

New strategies for heart failu ...... for heart failure phenotypes.

@nl

prefLabel

New strategies for heart failu ...... for heart failure phenotypes.

@ast

New strategies for heart failu ...... for heart failure phenotypes.

@en

New strategies for heart failu ...... for heart failure phenotypes.

@nl

P1433

Q34375466-8726B99F-3705-4E77-820A-BB107C0C8450

P1476

Q34375466-A4771F8C-1A6A-49BA-9425-76C4B7B59554

P2093

Q34375466-0C0976AA-8788-45B1-A1CD-0A902B40FCBB

Q34375466-11F93066-B57A-4924-ABA6-A661F5EB8845

Q34375466-467E7393-F637-4DBE-B80B-435E2D99AA87

Q34375466-4DBC2F49-1552-4D6C-B5E9-D11FC7E094F3

Q34375466-50CD6D12-1996-44B6-B01C-92F4F5818194

Q34375466-6E25ADCF-CDA7-4F34-B0CF-ABAF2180D695

Q34375466-71016C7A-D0B9-444C-81FF-9819C7B1D35D

Q34375466-777D7E61-D3A9-40F1-B0AF-BA39B8B7AF54

Q34375466-A0662367-9208-4BB9-AFB6-6D72F087EB5A

Q34375466-B214612A-41A6-4A67-AFBD-7FEBE6964026

P2860

Q34375466-0051C68D-2719-4D98-9EF9-00E649E2D916

Q34375466-016E21B4-055C-4457-8A61-1490CD7B66DB

Q34375466-016F34C5-C8A9-4016-8DB5-917F997E95C9

Q34375466-04F2E783-5A00-457B-9C55-B67C48746D23

Q34375466-098579F3-A476-4408-9B18-AEAAE1533D0E

Q34375466-0A663C4B-F0D5-454E-B35A-83C6C6DB2A7F

Q34375466-0B7CA486-C04E-4C87-9966-704375D69A1F

Q34375466-0C990C88-FD15-464F-9ACC-A946AC854EF7

Q34375466-0E5A2A97-0544-4FD7-ABC4-AA987BB2B247

Q34375466-1167943B-1C6F-47B7-9D4B-570FB0A32D1D

P304

Q34375466-DB935617-07BF-496C-A997-3CFBC60149FB

P31

Q34375466-404B23E2-3F91-4565-B51C-DA7FDD7FF624

P356

Q34375466-F32B6C3A-B8C0-4E60-9F69-1E5F06DB8DB8

P433

Q34375466-B666F57F-5099-4857-9554-16F5719EB93C

P478

Q34375466-49797B97-C2FD-43CD-858B-70B3967A9787

P50

Q34375466-358FC3D3-6D74-42BC-A919-E0DAB4278E50

Q34375466-561CBCDE-F68E-4927-8283-7E5FCBB7BC11

Q34375466-597E354F-0479-42B1-A722-5F5EBC4A3884

Q34375466-95A625DC-689B-44C8-A3DF-45259A1ABD00

Q34375466-9C42A8C3-4685-4313-BA94-886BF27B4688

Q34375466-A660BCF2-A8D3-4E1F-A165-918B997C5579

Q34375466-ACBEF41E-9B15-4D20-B722-330403CD6D5B

Q34375466-D26D10A5-4118-43C3-9F98-80F3D54F20DE

Q34375466-E2974610-31DF-4104-A096-796056C80129

P577

Q34375466-D3C11050-DBFF-4E38-A1AB-63791A7F088D

P5875

Q34375466-A8DBB412-D001-4A3D-96DF-54FB943E2A62

P698

Q34375466-3315D83C-6682-4503-A013-797066F2B77B

P921

Q34375466-ACF010F6-67A8-4B5A-93A2-95CC89C0ACDA

P932

Q34375466-C9A398FC-7935-473C-BAB1-5EBFACAF898D

P356

P1433

European Heart Journal

P1476

New strategies for heart failu ...... for heart failure phenotypes.

@en

P2093

Alan G Fraser

http://www.w3.org/2001/XMLSchema#string

Andrew J Stewart Coats

http://www.w3.org/2001/XMLSchema#string

Antonello Gavazzi

http://www.w3.org/2001/XMLSchema#string

Burkert M Pieske

http://www.w3.org/2001/XMLSchema#string

Carolyn S P Lam

http://www.w3.org/2001/XMLSchema#string

Carsten Tschöpe

http://www.w3.org/2001/XMLSchema#string

Daniel Levy

http://www.w3.org/2001/XMLSchema#string

Frank Edelmann

http://www.w3.org/2001/XMLSchema#string

Gerasimos S Filippatos

http://www.w3.org/2001/XMLSchema#string

Giuseppe Ambrosio

http://www.w3.org/2001/XMLSchema#string

P2860

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure

Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.

Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.

Effect of left bundle branch block on diastolic function in dilated cardiomyopathy

Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway

P304

2797-2815

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHU204

http://www.w3.org/2001/XMLSchema#string

P433

40

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Stefan D. Anker

Aldo P Maggioni

Carolyn S P Lam

Mihai Gheorghiade

Wendy Gattis Stough

P577

2014-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264630221

http://www.w3.org/2001/XMLSchema#string

P698

25104786

http://www.w3.org/2001/XMLSchema#string

P921

P932

4204003

http://www.w3.org/2001/XMLSchema#string